Humanigen (QB) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Humanigen Inc (QB) HGEN OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.99 20:00:00
Close Price Low Price High Price Open Price Previous Close
1.99 1.99
Bid Price Ask Price Spread News
1.36 2.10 0.74 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.99 USD

Humanigen (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 419.77M 210.94M 76.37M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.21M $ - 0.00% - -

more financials information »

Humanigen (QB) News

Date Time Source News Article
10/07/202016:31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
10/07/202016:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
10/02/202016:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
10/02/202016:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
9/22/202018:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
9/22/202017:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
9/22/202017:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months5.005.451.502.96931,766-3.01-60.2%
6 Months0.9476.790.7743.42576,9031.04110.14%
1 Year0.6216.790.303.31287,9311.37220.45%
3 Years0.756.790.1253.1497,0561.24165.33%
5 Years3.9918.260.1253.1766,641-2.00-50.13%

Humanigen (QB) Description

The Company is focused on developing its novel human granulocyte-macrophage colony-stimulating factor ("GM-CSF") neutralization and gene-knockout platforms and its portfolio of next-generation cell and gene therapies. The lead product candidate is lenzilumab, a proprietary Humaneered monoclonal antibody that has been demonstrated to neutralize GM-CSF. GM-CSF is thought of as a communication conduit between the innate and adaptive immune systems. Once initiated, the inflammatory cascade in certain cases may quickly evolve into a self-perpetuating "storm", frequently referred to as cytokine release syndrome, or CRS. The Company focuses on preventing and treating CRS. The Company is commencing a Phase III, potential registration, study of lenzilumab in patients hospitalized with severe pneumonia associated with COVID-19. The Company continues to pursue its programs to prevent or reduce the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell ("CAR-T") therapy and to prevent or treat graft-versus-host disease ("GvHD") in patients undergoing allogeneic hematopoietic stem cell transplantation ("HSCT"), including its collaboration with Kite Pharmaceuticals, Inc., a Gilead company ("Kite").
Your Recent History
Humanigen ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201027 07:27:24